BACE1 and diabetes mellitus: Recent studies suggest that NEAT1 and XIST, two important biomarkers in DM and AD, are upregulated in both diseases, which not only activate the Akt/mTOR signaling pathway but also dysregulate the expression of miR-124, resulting in an increase in BACE1 concentration and Aβ plaque deposition in the brain35–37.